neuren pharmaceuticals ltd.: nnz-2591 as a potential treatment for angelman syndrome
Published 2 years ago • 986 plays • Length 13:46Download video MP4
Download video MP3
Similar videos
-
22:47
2019 fast summit on angelman syndrome - nnz-2591 for as - dr. larry glass, neuren pharmaceuticals
-
8:46
2023 neuren pharmaceuticals update
-
15:09
background on neuren pharmaceuticals and nnz 2591 larry glass 2020 fast science summit
-
7:58
neuren pharmaceuticals 'in unique position' as it receives key approval for nnz-2591 trial
-
15:08
présentation de neuren pharmaceuticals et le développement de nnz-2591
-
29:12
neuren pharmaceuticals (asx:neu) - webinar presentation
-
14:45
neuren larry glass
-
![working to restore balance to brain function in fxs [trofinetide (nnz-2566, neuren pharmaceuticals)]](https://i.ytimg.com/vi/VPzWQCm0kJ0/mqdefault.jpg)
1:06:59
working to restore balance to brain function in fxs [trofinetide (nnz-2566, neuren pharmaceuticals)]
-
34:24
2019 fast summit on angelman syndrome - aso for potential treatment of as - genetx biotherapeutics
-
37:09
genetic approaches for treating angelman syndrome
-
40:37
angelman syndrome clinical trial update - ov101
-
24:27
ionis pharmaceuticals: angelman syndrome program update
-
50:18
twilight briefing with neuren and dimerix
-
22:38
interview with neuren pharmaceuticals about an upcoming phelan-mcdermid clinical trial
-
1:29:21
pharma industry update session 2022 asf family conference
-
14:21
peak tv - neuren pharmaceuticals asx:neu
-
42:41
tremendous hope that we will get to the finish line!